RESUMEN
BACKGROUND: We previously demonstrated that the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statins) play an important role in the regulation of alloimmune responses. However, little is known regarding the effects of statin on allograft protection or donor-specific antibodies (DSA). In this study, we investigated the graft-protective and immunomodulatory effects of rosuvastatin in a model of fully major histocompatibility complex-mismatched murine cardiac allograft transplantation. METHODS: CBA mice underwent transplantation of C57BL/6 (B6) hearts and received 50 and 500 µg/kg/day of rosuvastatin from the day of transplantation until seven days after the completion of transplantation. To confirm the requirement for regulatory T cells (Tregs), we administered an anti-interleukin-2 receptor alpha antibody (PC-61) to rosuvastatin-treated CBA recipients. Additionally, histological and fluorescent staining, cell proliferation analysis, flow cytometry, and DSA measurements were performed. RESULTS: CBA recipients with no treatment rejected B6 cardiac graft acutely (median survival time [MST], 7 days). CBA mice treated with 500 µg/kg/day of rosuvastatin prolonged allograft survival (MSTs, 77 days). Fluorescent staining studies showed that rosuvastatin-treated recipients had strong aggregation of CD4+Foxp3+ cells in the myocardium and around the coronary arteries of cardiac allografts two weeks after grafting. Flow cytometry studies performed two weeks after transplantation showed an increased number of splenic CD4+CD25+Foxp3+ T cells in rosuvastatin-treated recipients. The addition of rosuvastatin to mixed leukocyte cultures suppressed cell proliferation by increasing the number of CD4+CD25+Foxp3+ Tregs. Additionally, Tregs suppressed DSA production in rosuvastatin-treated recipients. CONCLUSION: Rosuvastatin treatment may be a complementary graft-protective strategy for suppressing DSA production in the acute phase, driven by the promotion of splenic and graft-infiltrating CD4+CD25+Foxp3+ Tregs.
Asunto(s)
Trasplante de Corazón , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Rosuvastatina Cálcica , Linfocitos T Reguladores , Animales , Rosuvastatina Cálcica/farmacología , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/inmunología , Ratones , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Rechazo de Injerto/prevención & control , Rechazo de Injerto/inmunología , Supervivencia de Injerto/efectos de los fármacos , Supervivencia de Injerto/inmunología , Subunidad alfa del Receptor de Interleucina-2/inmunología , Masculino , Factores de Transcripción Forkhead/metabolismo , Modelos Animales de Enfermedad , Citometría de FlujoRESUMEN
BACKGROUND: We demonstrated that an agonistic anti-B and T lymphocyte attenuator antibody (3C10) prolonged cardiac survival by inducing regulatory T cells (Treg). However, the mechanisms of immune tolerance in the recipients remained unclear. In this study, we investigated the graft-protective and intercellular immunomodulatory effects of adoptive transfer (AT) of 3C10-induced Tregs in a murine cardiac allograft transplant model. METHODS: Thirty days after transplantation of a C57BL/6 heart into the primary 3C10-treated CBA recipients, splenic CD4+CD25+ cells from these recipients (3C10/AT group) or naïve CBA mice (no-treatment group) were adoptively transferred into secondary CBA recipients with a C57BL/6 heart. To confirm the requirement for 3C10-induced Tregs, we administered an anti-interleukin-2 receptor alpha antibody (PC-61) to secondary CBA recipients. Additionally, histologic and fluorescent staining, cell proliferation analysis, flow cytometry, and donor-specific antibody (DSA) measurements were performed. RESULTS: 3C10/AT-treated CBA recipients resulted in significantly prolonged allograft survival (median survival time [MST], >50 days). Allografts displayed prolonged function with preservation of vessel structure by maintaining high numbers of splenic CD4+CD25+Foxp3+ Treg and intramyocardial CD4+Foxp3+ cells. DSA levels were suppressed in 3C10/AT-treated CBA recipients. Moreover, PC-61 administration resulted in a shorter MSTs of cardiac allograft survivals, a detrimental increase in DSA production, and enhanced expression of programmed cell death (PD)-1. CONCLUSION: AT of 3C10-induced Tregs may be a promising graft-protective strategy to prolong allograft survival and suppress DSA production, driven by the promotion of splenic and graft-infiltrating Tregs and collaboration with PD-1+ T cells and Treg.
Asunto(s)
Traslado Adoptivo , Supervivencia de Injerto , Trasplante de Corazón , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Linfocitos T Reguladores , Animales , Linfocitos T Reguladores/inmunología , Ratones , Supervivencia de Injerto/efectos de los fármacos , Subunidad alfa del Receptor de Interleucina-2/inmunología , Anticuerpos Monoclonales/farmacología , Masculino , Receptores Inmunológicos/metabolismo , Aloinjertos , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Ratones Endogámicos BALB CRESUMEN
BACKGROUND: Gefitinib and erlotinib, are epidermal growth factor receptor tyrosine kinase inhibitors, and are currently recommended for non-small cell lung cancer stage IV in the elderly and in patients with decreased performance status in the Japanese Lung Cancer Society Guideline, but they occasionally caused severe hepatotoxicity requiring postponement or modification of treatment. However, little is known about the risk factors for hepatotoxicity in patients receiving gefitinib and erlotinib. In this study, we investigated the factors influencing hepatotoxicity in Japanese non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib monotherapy. METHODS: Japanese patients with NSCLC who started gefitinib or erlotinib monotherapy from January 2005 to December 2017 at Kanazawa University Hospital or Kanazawa Medical University Hospital were included in this study. Factors affecting hepatotoxicity were retrospectively investigated by multiple logistic regression analysis. RESULTS: A total of 102 patients who received gefitinib and 95 patients who received erlotinib were included in the analysis. In the gefitinib group, a body mass index (BMI) ≥ 25 was associated with an increased risk of hepatotoxicity (OR = 4.571, 95% CI = 1.486-14.056, P = 0.008). In the erlotinib group, concomitant use of acid-suppressing medications (AS), namely proton pump inhibitors or histamine-2 receptor antagonists, was associated with a reduced risk of hepatotoxicity (OR = 0.341, 95% CI = 0.129-0.900, P = 0.030). CONCLUSIONS: BMI ≥ 25 in patients treated with gefitinib increased the risk of hepatotoxicity. In contrast, AS combination with erlotinib reduced the risk of hepatotoxicity. Thus, because different factors influence the risk of hepatotoxicity, monitoring for adverse events should take into account patient background factors and concomitant medications.
RESUMEN
OBJECTIVE: To evaluate the effects of combining one-lung ventilation and carbon dioxide insufflation (OLV-CDI) on intrathoracic working space (determined by means of CT) during thoracoscopy in dogs and investigate conditions that could safely improve working space compared with OLV alone. ANIMALS: 6 healthy Beagles. PROCEDURES: Dogs were anesthetized, and right- or left-sided (n = 3/side) OLV was instituted. On the blocked side, a laparoscopic trocar sleeve was placed in the ninth intercostal space for CDI. CT was performed under 3 conditions: with OLV alone, with OLV-CDI at an intrapleural pressure (IPP) of 3 mm Hg, and with OLV-CDI at an IPP of 5 mm Hg. Working space volume (WSV), ventilation space volume (VSV), and thoracic cavity volume (TCV) were determined from CT images. RESULTS: With OLV-CDI at an IPP of 3 or 5 mm Hg, WSV and TCV were significantly increased, compared with values obtained during OLV alone. With OLV-CDI at an IPP of 5 mm Hg, VSV and Spo2 were significantly decreased, compared with values obtained during OLV alone. Additionally, contralateral pneumothorax was observed in 4 dogs at an IPP of 5 mm Hg. CLINICAL RELEVANCE: Combining OLV and CDI could provide a larger working space than OLV alone, even with an IPP of 3 mm Hg, in dogs of limited size. However, an evaluation of the effects on oxygenation and cardiovascular variables is needed before clinical use.
Asunto(s)
Insuflación , Ventilación Unipulmonar , Animales , Dióxido de Carbono , Perros , Insuflación/veterinaria , Ventilación Unipulmonar/veterinaria , Respiración , Respiración Artificial/veterinaria , Toracoscopía/métodos , Toracoscopía/veterinariaRESUMEN
Recent advances in chemotherapy have led to the emergence of new types of anticancer agents. With these advances, cases of side effects that have not been witnessed in the past have emerged. The systems of side effect evaluation and their grading have been based on the existing knowledge, such as the CTCAE (Common Terminology Standard for Adverse Events) for evaluating adverse drug reactions in cancer chemotherapy clinical trials. Therefore, new types of side effects may be overlooked or underestimated. Blinatumomab is a bispecific T-cell-engager (BiTE) antibody with specificity for CD19 on B cells and CD3 on T cells. Neurological events, such as neuropathy and encephalopathy, are serious side effects of BiTE antibodies. We encountered a case of a 62-year-old woman who experienced short-term memory impairment and dysgraphia after the first blinatumomab administration for Philadelphia chromosome negative (Ph-) B-cell acute lymphoblastic leukemia (ALL). The CTCAE does not include dysgraphia as a classifier for antibody therapies, such as blinatumomab, and immune effector cell-associated neurotoxicity syndrome, which is defined as a Chimeric antigen receptor T cell therapy-related toxicity; dysgraphia is included in the list of symptoms but is not graded. In this case, the severity of dysgraphia differed depending on the complexity of the letters examined. There is no report that the severity of dysgraphia depends on the letters' complexity, and therefore, it may be overlooked when using simple letters. We have reported the characteristics of dysgraphia in this case and the differences observed when judging different letters.
Asunto(s)
Agrafia , Anticuerpos Biespecíficos , Antineoplásicos , Agrafia/inducido químicamente , Agrafia/tratamiento farmacológico , Anticuerpos Biespecíficos/efectos adversos , Antígenos CD19 , Antineoplásicos/efectos adversos , Femenino , Escritura Manual , Humanos , Persona de Mediana EdadRESUMEN
Saireito (Tsumura Japan [TJ]-114) could induce long-term cardiac allograft survival through the generation of CD4+CD25+Foxp3+ cells (regulatory T cells, Tregs). However, little is known regarding the effects of TJ-114 on the suppression of donor-specific antibody (DSA). Therefore, we aimed to further investigate the suppressive properties of TJ-114 and its effects on DSA production in a murine cardiac allograft model. CBA mice underwent transplantation of C57BL/6 hearts and were subsequently administered TJ-114 (2g/kg/d) from the day of transplantation until 7 days afterward. TJ-114-treated recipients demonstrated upregulation of splenic Tregs and suppressed DSA production at postoperative day 10 relative to untreated controls. This effect was sustained at postoperative day 20 even when TJ-114 administration was stopped at day 7. To then investigate the involvement of Tregs in the suppression of DSA production, anti-interleukin-2 receptor alpha antibody (PC-61) was administered to deplete Treg populations in TJ-114-treated CBA recipients on postoperative days 0, 3, 6, and 9 or 20, 23, and 26. At day 10, CBA recipients that received PC-61 with TJ-114 demonstrated suppression of DSA production similar to those receiving only TJ-114. Nonetheless, when mice were treated with PC-61 at days 20, 23, and 26, DSA levels gradually increased to levels comparable to those of untreated mice by day 29, suggesting that Tregs are necessary to sustain the suppression of DSA once the effects of TJ-114 have subsided. Taken together, TJ-114 may be a promising therapeutic strategy to prolong allograft survival through its combined immunosuppressive effects in inducing Tregs and suppressing DSA production.
Asunto(s)
Trasplante de Corazón , Linfocitos T Reguladores , Animales , Medicamentos Herbarios Chinos , Supervivencia de Injerto , Trasplante de Corazón/efectos adversos , Humanos , Japón , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBARESUMEN
Recent evidence has pointed to the promising benefits of using specific immunosuppressive herbal compounds to prolong transplant allograft survival. In this study, we investigated the effects of glycyrrhizic acid (GA), a major component of licorice, in a model of murine heart transplantation. CBA (H2k) mice were transplanted with a fully-MHC mismatched C57BL/6 (H2b) heart allograft and subsequently received daily intraperitoneal administration of normal saline or 0.02, 0.2, or 2.0 mg/d of GA for 7 consecutive days. Untreated CBA recipients, with a median survival time (MST) of 7 days, and groups receiving 0.02mg/d (MST, 8 days) or 0.2mg/d (MST, 9 days) of GA acutely rejected C57BL/6 cardiac allografts. But mice treated with 2.0 mg/d of GA demonstrated significant prolongation of allografts (MST, 23 days). Histologic studies showed that cardiac allografts from GA-treated CBA recipients had preserved graft and vessel structure. Moreover, flow cytometric study showed that the percentage of CD4+CD25+Foxp3+ cell (regulatory T cell [Treg]) populations were increased in GA-treated CBA recipients. In a mixed leukocyte culture, splenocytes from GA-treated mice demonstrated suppressed allo-proliferation, in which interleukin (IL)-2 and interferon gamma production were downregulated and IL-10 secretion was upregulated. In conclusion, GA may be a novel promising therapeutic agent to prolong cardiac allograft survival through direct anti-inflammatory effects and induction of Treg populations.
Asunto(s)
Glycyrrhiza , Trasplante de Corazón , Traslado Adoptivo , Aloinjertos , Animales , Ácido Glicirrínico/farmacología , Supervivencia de Injerto , Trasplante de Corazón/efectos adversos , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Linfocitos T ReguladoresRESUMEN
BACKGROUND: Generally, graft function in the murine cardiac allograft transplant model is assessed daily by palpating the heart for evidence of contraction. To our knowledge, few reports have investigated the correlation of cardiac graft function using echocardiography and immunohistochemical studies. In this study, we investigated the efficacy of echocardiographic and histologic evaluation of alloimmune responses in the acute phase of murine cardiac allografts. METHODS: Fully vascularized heterotopic hearts from CBA (allogeneic group) or C57BL/6 (syngeneic group) donors were transplanted into C57BL/6 recipients using microsurgical techniques. Fluctuations in heart rate, left ventricular ejection fraction (LVEF), left ventricular functional shortening (LVFS), right ventricular outflow tract maximal systolic velocity (RVOT Vmax), and RVOT velocity time integral (RVOT VTI) were evaluated on postoperative days (PODs) 1, 3, 5, 7, and 9 after transplantation using an ultrasonic device. Histologic studies were also performed. RESULTS: The syngeneic group did not show a complete cessation of heartbeat or deterioration of cardiac function. CBA recipients in the allogeneic group rejected cardiac allografts on POD 9 after grafting. LVEF and LVFS in the allogeneic group gradually decreased on POD 9. Consistent with the time-course echocardiographic evaluation, histologic studies showed gradual atrophy of the left ventricle. In contrast, RVOT Vmax and RVOT VTI in the allogeneic group were not significantly different during the observation period. Additionally, the thickness of the right ventricular wall did not change until POD 7. CONCLUSION: The present findings suggested that echocardiography may help to evaluate time-course murine cardiac graft function through left ventricular parameters such as LVEF and LVFS.
Asunto(s)
Trasplante de Corazón , Animales , Ecocardiografía , Trasplante de Corazón/efectos adversos , Trasplante de Corazón/métodos , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Volumen Sistólico , Donantes de Tejidos , Función Ventricular IzquierdaRESUMEN
Thrombomodulin is used to manage disseminated intravascular coagulation. In our murine heart transplantation model, the administration of recombinant human soluble thrombomodulin (rTM) could induce the prolongation of cardiac allograft survival. However, there are limited data on the graft protective effects of each r domain (D1, D2, and D3). In this study, we investigated the effects of each domain of rTM on alloimmune responses in a murine model of cardiac allograft transplantation. Fully vascularized heterotopic hearts from C57BL/6 donors were transplanted into CBA recipients using microsurgical techniques. CBA mice that underwent transplantation of C57BL/6 cardiac allografts were assigned to 4 groups: no treatment and each domain-exposed group. The dosage of each domain was determined based on our previous experiments. Flow cytometry and histologic studies were performed to determine whether Foxp3+ regulatory T cells were generated. Untreated and D2-exposed CBA recipients acutely rejected C57BL/6 cardiac allografts within 9 days. Administration of D3 resulted in modest prolongation of allograft survival, and administration of D1 significantly prolonged allograft survival. Histologic studies showed that myocardial damage of allografts from D1- and D3-exposed CBA recipients was controlled compared with that of untreated recipients. In particular, the CD4+CD25+Foxp3+ cell population in the splenocytes of D1-exposed CBA recipients was increased. In conclusion, D1 in rTM could help prolong cardiac allograft survival through regulatory T cell induction and graft protective effects.
Asunto(s)
Trasplante de Corazón , Trombomodulina , Aloinjertos , Animales , Supervivencia de Injerto , Trasplante de Corazón/efectos adversos , Trasplante de Corazón/métodos , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Linfocitos T ReguladoresRESUMEN
BACKGROUND: Myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are attractive immune cells to induce immune tolerance. To explore a strategy for improving the efficacy of MDSC therapies, we examined the impact of adoptive transfer of several types of MDSCs on graft rejection in a murine heart transplantation model. METHODS: We analyzed the effects of induced syngeneic and allogeneic bone marrow-derived MDSCs (BM-MDSCs) on graft survival and suppressive capacity. We also compared the ability of syngeneic monocytic MDSCs (Mo-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs) to inhibit graft rejection and investigated the suppression mechanisms. RESULTS: Both syngeneic and allogeneic donor- or allogeneic third-party-derived BM-MDSCs prolonged graft survival, although syngeneic BM-MDSCs inhibited anti-donor immune responses most effectively in vitro. Syngeneic Mo-MDSCs, rather than PMN-MDSCs, were responsible for immune suppression through downregulating inducible nitric oxide synthase (iNOS) and expanded naturally occurring thymic originated Treg (nTreg) in vitro. Adoptive transfer of Mo-MDSCs, but not PMN-MDSCs, prolonged graft survival and increased Treg infiltration into the graft heart. CONCLUSION: Recipient-derived Mo-MDSCs are most effective in prolonging graft survival via inhibiting T cell response and nTreg infiltration.
Asunto(s)
Rechazo de Injerto/terapia , Trasplante de Corazón , Terapia de Inmunosupresión/métodos , Monocitos/inmunología , Células Supresoras de Origen Mieloide/inmunología , Linfocitos T Reguladores/inmunología , Traslado Adoptivo , Animales , Células Cultivadas , Modelos Animales de Enfermedad , Supervivencia de Injerto , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Células Supresoras de Origen Mieloide/trasplante , Óxido Nítrico Sintasa de Tipo II/metabolismo , Trasplante HomólogoRESUMEN
OBJECTIVE: A sheet material is widely used to repair pleural defects due to its excellent pressure resistance. We examined the long-term effects of sheet materials using an animal pleural defect model. METHODS: Beagles were used for this study. The 5-mm circular pleural defects were created at 2 sites on each of the anterior, medial, and posterior lobe and repaired using a 2 cm square sheet material. The frequency of adhesion of those sheets to the thoracic walls and histological changes was examined after 6 months. In this study, three types of sheet materials were examined: polyglycolic acid, nano-polyglycolic acid, and oxidized regenerated cellulose where each sheet was tested with or without coating with fibrin glue, for a total of 6 groups. Each group contained an equal number of defect sites and evaluation of 12 defect sites was conducted. RESULTS: Adhesion was observed in 16 of 72 sites (22%). Presence or absence of adhesion was not affected by the repair method or by the type of sheet material used. However, the use of fibrin glue significantly reduced the occurrence of adhesion (p = 0.023). At the defected sites, the posterior lobe showed significantly less adhesion (p = 0.019). Histologically, the sheet materials caused a thickening of the pleural wall 6-10 times thicker than the normal pleural wall. CONCLUSION: No statistically significant differences regarding the presence or absence of adhesion to the thoracic wall were found among the sheet materials. The use of fibrin glue significantly reduced the adhesion to the thoracic wall.
Asunto(s)
Celulosa Oxidada/uso terapéutico , Pleura/cirugía , Ácido Poliglicólico/uso terapéutico , Herida Quirúrgica/cirugía , Animales , Modelos Animales de Enfermedad , Perros , Adhesivo de Tejido de Fibrina , Nanoestructuras/uso terapéutico , Pleura/patología , Pared Torácica , Factores de Tiempo , Adherencias Tisulares/etiologíaRESUMEN
Rotavirus gastroenteritis causes substantial morbidity and mortality worldwide in children. We report three infants with rotavirus gastroenteritis complicated by various severity of gastrointestinal bleeding. Two patients (cases 1 and 2) recovered completely without any specific treatments. One patient (case 3) died despite extensive treatments including a red blood cell transfusion and endoscopic hemostatic therapy. Rotavirus genotypes G1P[8] and G9P[8] were detected in cases 2 and 3, respectively. Rotavirus antigenemia levels were not high at the onset of melena, suggesting that systemic rotaviral infection does not play an important role in causing melena.
Asunto(s)
Gastroenteritis/complicaciones , Gastroenteritis/diagnóstico , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/patología , Infecciones por Rotavirus/complicaciones , Infecciones por Rotavirus/diagnóstico , Rotavirus/aislamiento & purificación , Antígenos Virales/sangre , Resultado Fatal , Femenino , Gastroenteritis/virología , Genotipo , Humanos , Lactante , Masculino , Rotavirus/clasificación , Rotavirus/genética , Infecciones por Rotavirus/virología , Viremia/diagnósticoRESUMEN
Children with renal diseases are typically treated with immunosuppressive drugs, which place them at high risk of reactivation of the BK virus (BKV). Currently, little is known about the impact of immunosuppressive drugs on the kinetics of urinary shedding of BKV and viral reactivation in pediatric patients with renal diseases. Urine samples were collected monthly for 1 year from 20 children (median age, 9 years; range, 4-15 years) with renal diseases and subjected to real-time PCR. Urinary shedding of BKV was detected in 35% (7/20) of the patients, three of these patients having persistent viral DNA excretion (two cases, twelve times; one case, four times) and four having intermittent viral DNA excretion. Thirty-four of the 240 urine samples contained BKV DNA (median copy numbers, 5.66 log copies/mL; range, 2.45-7.69 log copies/mL). In two of the cases with persistent viral shedding, high copy numbers (range, 4.57-7.69 log copies/mL) of BKV DNA were detected in all 12 urine samples collected. In the other case with persistent viral excretion, a range of 2.45-3.98 log copies/mL of BKV DNA was detected in the four urine samples collected between the 9th and 12th sampling time points. Additionally, high copy numbers (range, 3.12-4.36 log copies/mL) of BKV DNA were detected intermittently in the urine samples of the other four cases. No remarkable correlations were found between the kinetics of BKV DNA loads and urinary findings such as proteinuria and hematuria. The present data demonstrate the kinetics of urinary BKV shedding in pediatric patients with renal diseases. Additionally, no pathogenic role for BKV infection was identified.
Asunto(s)
Virus BK/aislamiento & purificación , Enfermedades Renales/virología , Infecciones por Polyomavirus/virología , Infecciones Tumorales por Virus/virología , Orina/virología , Esparcimiento de Virus , Adolescente , Niño , Preescolar , ADN Viral/orina , Femenino , Humanos , Masculino , Reacción en Cadena en Tiempo Real de la Polimerasa , Carga ViralRESUMEN
Cytomegalovirus (CMV), human herpesvirus 6 (HHV-6) and 7 (HHV-7) are important pathogens in immunocompromised patients. To elucidate the kinetics of the three ß-herpesviruses in saliva and urine samples were collected serially from children with renal diseases. Twenty children with renal diseases were enrolled in this study. A total of 240 saliva and urine samples were collected monthly from the patients over a 1-year period. Viral DNAs loads were measured by real-time PCR. In 10 CMV seropositive patients CMV DNA was detected rarely in saliva and CMV DNA load was lower than the other two ß-herpesviruses DNA loads. All patients were seropositive for HHV-6B and the virus was detected frequently in saliva. Two of 20 patients were HHV-7 seronegative. High copies of viral DNA were detected continuously in saliva of the HHV-7 seropositive patients. Although neither CMV nor HHV-6B DNA load was different among the three renal diseases, HHV-7 DNA load was different among the diseases (P = 0.039). HHV-6B DNA loads were significantly higher in patients with immunosuppressive treatment compared to those without treatment (P = 0.013). Although CMV DNA was detected in urine samples collected from 5 of 10 CMV seropositive patients, HHV-6B and HHV-7 DNA were detected at relatively low frequencies in urine. No remarkable temporal associations between viral DNA excretion and proteinuria or immunosuppressive treatment were demonstrated. The pattern of viral DNA excretion in saliva and urine were different among the three viruses. No temporal correlation was observed between viral infection and renal diseases.
Asunto(s)
Betaherpesvirinae/aislamiento & purificación , Infecciones por Herpesviridae/virología , Enfermedades Renales/virología , Saliva/virología , Orina/virología , Esparcimiento de Virus , Adolescente , Niño , Preescolar , ADN Viral/genética , ADN Viral/aislamiento & purificación , Femenino , Humanos , Estudios Longitudinales , Masculino , Reacción en Cadena en Tiempo Real de la Polimerasa , Carga ViralRESUMEN
Rapid diagnosis of Mycoplasma pneumoniae pneumonia is required for treatment with effective antimicrobial agents without delay; however, this capacity has not yet been established in clinical practice. Recently, a novel nucleic acid amplification method termed loop-mediated isothermal amplification (LAMP) has been used to rapidly diagnose various infectious diseases. In this study, we prospectively evaluated the efficacy of the LAMP assay to rapidly diagnose M. pneumoniae pneumonia in clinical practice. Three hundred sixty-eight children (median age, 3.8 years; range, 0.1-14.3 years) admitted to our hospital between April 2009 and March 2010 for community-acquired pneumonia were enrolled in this study. We obtained throat swabs on admission to detect M. pneumoniae DNA and paired serum samples on admission and at discharge to assay M. pneumoniae antibody titers. M. pneumoniae pneumonia was diagnosed by either a positive LAMP assay or a fourfold or greater increase in antibody titer. Overall, 46 children (12.5% of the patients with pneumonia) were diagnosed with M. pneumoniae pneumonia; of these, 27 (58.7%) were aged less than 6 years. Of the aforementioned 46 children, 38 (82.6%) and 37 (80.4%) were identified by LAMP and serology, respectively. When the results of serology were taken as the standard, the sensitivity and specificity and positive and negative predictive values of the LAMP assay were 78.4%, 97.3%, 76.3%, and 97.6%, respectively. We concluded the LAMP assay may be useful for rapid diagnosis of M. pneumoniae pneumonia.
Asunto(s)
Infecciones Comunitarias Adquiridas/microbiología , Mycoplasma pneumoniae/aislamiento & purificación , Técnicas de Amplificación de Ácido Nucleico/métodos , Neumonía por Mycoplasma/microbiología , Pruebas Serológicas/métodos , Adolescente , Anticuerpos Antibacterianos/sangre , Niño , Preescolar , Infecciones Comunitarias Adquiridas/inmunología , ADN Bacteriano/análisis , Femenino , Humanos , Lactante , Japón/epidemiología , Masculino , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/inmunología , Nasofaringe/microbiología , Neumonía por Mycoplasma/inmunología , Estudios Prospectivos , Juego de Reactivos para Diagnóstico , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Several studies in Western countries have found that lower respiratory tract infections (LRTIs) caused by the respiratory syncytial virus (RSV) in infancy may subsequently trigger the development of asthma. In this study, we enrolled 262 infants under the age of 3 who had been admitted to our hospital with LRTI between September 2002 and August 2003. RSV infection was diagnosed in these patients using an RSV rapid diagnostic kit and by measuring antibody titers in paired serum samples. In March 2009, we sent questionnaires on post-discharge allergic conditions to the families of the 249 patients, excluding 13 who had a prior history of asthma. A total of 133 responses were received (response rate, 53.4%); RSV was detected in 36 patients of the RSV group and 97 patients of the non-RSV group. Wheezing was experienced post-discharge by 10 patients in the RSV group (27.8%) and 32 in the non-RSV group (33.0%) (P = 0.57). Four patients in the RSV group (11.1%) and 6 in the non-RSV group (6.2%) (P = 0.34) were treated for asthma. This study revealed that RSV LRTI in infancy does not predispose children to subsequent development of asthma at the age of 7 years and 7 months. We believe that this is the first Japanese survey that has examined the relationship between RSV LRTI in infancy and the subsequent development of asthma.
Asunto(s)
Asma/epidemiología , Asma/virología , Infecciones por Virus Sincitial Respiratorio/complicaciones , Virus Sincitial Respiratorio Humano/inmunología , Virus Sincitial Respiratorio Humano/aislamiento & purificación , Virus Sincitiales Respiratorios/aislamiento & purificación , Infecciones del Sistema Respiratorio/complicaciones , Pueblo Asiatico , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Prevalencia , Infecciones por Virus Sincitial Respiratorio/virología , Virus Sincitiales Respiratorios/patogenicidad , Infecciones del Sistema Respiratorio/virología , Encuestas y CuestionariosRESUMEN
We report a previously healthy 14-month-old boy who developed community-acquired Acinetobacter baumannii meningitis. He had no history of immunodeficiency, and was brought to Konan Kosei Hospital with a high fever and vomiting. His consciousness was clear, but neck stiffness was noted. Examination of the cerebrospinal fluid (CSF) revealed a cell count of 10 112/microl; protein, 216 mg/dl; and glucose, 9 mg/dl. A CSF test kit for bacterial capsular antigens (Pastorex Meningitis; Bio-Rad Laboratories) was positive for Haemophilus influenzae type b antigen. On day 3 of admission, the microorganism isolated by CSF culture was identified as A. baumannii. Therefore, his treatment was changed to meropenem hydrate from the initial therapy with panipenem/betamipron and ceftriaxone sodium hydrate. Because the CSF cell count remained elevated, meropenem hydrate was administered for a total of 19 days. The meningitis resolved with no sequelae.